Piritramide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Piritramide is a synthetic opioid used in the treatment of severe pain.
- Generic Name
- Piritramide
- DrugBank Accession Number
- DB12492
- Background
Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 430.5851
Monoisotopic: 430.27326173 - Chemical Formula
- C27H34N4O
- Synonyms
- Piritramida
- Piritramide
- Piritramidum
- External IDs
- IDS-NP-013
- R 3365
- R-3365
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Severe pain •••••••••••• •••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Piritramide is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Piritramide. Acetophenazine The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Piritramide. Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Piritramide. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Piritramide. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Dipidolor / Piridolan
Categories
- ATC Codes
- N02AC03 — Piritramide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylacetonitriles
- Direct Parent
- Diphenylacetonitriles
- Alternative Parents
- Diphenylmethanes / Alpha amino acid amides / Piperidinecarboxamides / Aralkylamines / Aminopiperidines / Trialkylamines / Primary carboxylic acid amides / Nitriles / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- 4-aminopiperidine / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Carbonitrile / Carbonyl group show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4RP92LYZ2F
- CAS number
- 302-41-0
- InChI Key
- IHEHEFLXQFOQJO-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)
- IUPAC Name
- 1'-(3-cyano-3,3-diphenylpropyl)-[1,4'-bipiperidine]-4'-carboxamide
- SMILES
- NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1
References
- General References
- BASG Product Information: Piritramid-hameln (piritramide) solution for injection [Link]
- External Links
- Human Metabolome Database
- HMDB0041990
- PubChem Compound
- 9331
- PubChem Substance
- 347828727
- ChemSpider
- 8967
- 8354
- ChEBI
- 135699
- ChEMBL
- CHEMBL559288
- ZINC
- ZINC000000538198
- Wikipedia
- Piritramide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Supportive Care Post Operative Nausea and Vomiting (PONV) / Postoperative pain 1 4 Completed Treatment Colon Cancer / Minimal Residual Disease 1 4 Completed Treatment Postoperative pain 1 Not Available Completed Treatment Analgesia / Cardiac Diseases / Surgery 1 Not Available Completed Treatment Aortic Valve Surgery / Postoperative pain 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular; Intravenous; Subcutaneous 7.5 mg/ml Injection, solution Intramuscular; Intravenous 7.5 mg/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00998 mg/mL ALOGPS logP 3.71 ALOGPS logP 3.39 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 15.72 Chemaxon pKa (Strongest Basic) 8.87 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 73.36 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 139.81 m3·mol-1 Chemaxon Polarizability 49.45 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-008i-4967000000-98351d91fa44f62e846d Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0002900000-c756c166782dfe1c1862 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-01ba-0009000000-edd4ab20cec2e027f203 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0000900000-9d6306d33bfc31781ed2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-008c-0968300000-378ee069ee855f8a211f Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0kdj-0009800000-ad41113c97f982a69c20 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-1295000000-34c9f8ec55e4dc3c6030 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 223.7298342 predictedDarkChem Lite v0.1.0 [M-H]- 223.9248342 predictedDarkChem Lite v0.1.0 [M-H]- 203.35986 predictedDeepCCS 1.0 (2019) [M+H]+ 224.1545342 predictedDarkChem Lite v0.1.0 [M+H]+ 223.6624342 predictedDarkChem Lite v0.1.0 [M+H]+ 205.71785 predictedDeepCCS 1.0 (2019) [M+Na]+ 223.8825342 predictedDarkChem Lite v0.1.0 [M+Na]+ 224.1821342 predictedDarkChem Lite v0.1.0 [M+Na]+ 212.35698 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:35 / Updated at July 03, 2021 01:49